Publications

New Directions Newsletter

Download the 2010 Lung Cancer Alliance New Directions Newsletter (.pdf)

Download the 2009 Lung Cancer Alliance New Directions Newsletter (.pdf)

Lung Cancer Alliance Times

Summer 2010 (.pdf)

Fall 2009 (.pdf)

January 2009 (.pdf)

Summer 2008 (.pdf)

Winter 2008 (.pdf)

LCA Clinical Trials Education

November 2009 (.pdf)

December 2008 (.pdf)

November 2007 (.pdf)

December 2006 (.pdf)*

Spirit and Breath Newsletter

Fall 2007 (.pdf)

2006 - Oct/Nov (.pdf)

2006 - July (.pdf)
2006-March (.pdf)

2005-Fall (.pdf)

2005 - Spring (.pdf)
2004 - Fall (.pdf) | 2004 - Summer (.pdf) | 2004 - Spring (.pdf)
2003 - Fall (.pdf) | 2003 - Summer (.pdf)

Frankly Speaking about Lung Cancer
Read More

Outside Scientific Research

An Actuarial Approach to Comparing Early Stage and Late Stage Lung Cancer Mortality and Survival - Conducted by Milliman, Inc.

* - Correction to December 2006 New Directions newsletter. Please note the following:
Page 3 of the New Directions newsletter incorrectly indicated Avastin for non-small cell lung cancer was approved for "Second or Third Line" Treatment and in the first of two references to the clinical trial that led to this approval, misstated the trial's number. The correct information is:

1. Avastin is specifically approved for first-line, non-squamous, non-small cell lung cancer (NSCLC) in combination with platinum based chemotherapy for people who have unresectable, locally advanced, recurrent or metastatic NSCLC. First-line (in this case) refers previous chemotherapy treatment for lung cancer.

2. The pivotal clinical trials that led to FDA approving Avastin for this use was E4599 (not E4559).